drugset / Trial / NCT04106804

Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker

NCT04106804

Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

Observation has pointed out, that osteitis present in the MRI scans, predicts bone erosion and that this in accordance with the concept by underlining the importance of bone marrow involvement in arthritis \[Krabben A, 2013\]. Abatacept with its favourable safety profile preferentially interrupts activation of naïve T cells and perhaps makes the strongest case for exploiting co-stimulatory blockade during the earliest detectable phase of the adaptive immune response at a time when predisposition to autoimmune disease can be detected.

Timeline

Start
2018-06-06
Primary completion
2021-08
Completion
2022-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 125 mg/ml Subcutaneous

Indications

No indication recorded.